Recent insights in rheumatoid arthritis (RA) necessitated updating the European League
Against Rheumatism (EULAR) RA management recommendations. A large international …

New treatment strategies have substantially changed the course of rheumatoid arthritis.
Many patients can achieve remission if the disease is recognised early and is treated …

Objectives Since the 2007 recommendations for the management of early arthritis have
been presented, considerable research has been published in the field of early arthritis …

Intravenous (IV) and subcutaneous (SC) tocilizumab (RoActemra®), an IL-6 receptor
antagonist, are approved (±methotrexate) in numerous countries throughout the world, for …

Heat shock proteins (HSPs) play cytoprotective activities under pathological conditions
through the initiation of protein folding, repair, refolding of misfolded peptides, and possible …

Background Baricitinib is an oral, reversible, selective Janus kinase 1 and 2 inhibitor.
Methods In this phase III, double-blind 24-week study, 684 biologic disease-modifying …

Objectives To update the evidence for the efficacy of biological disease-modifying
antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) to inform …

Historically, periodontal disease (gingivitis and periodontitis) has been recognized as being
primarily of bacterial origin. However, recent evidence indicates that while bacteria are …

Objective To investigate the predictive value of baseline depression/anxiety on the
likelihood of achieving joint remission in rheumatoid arthritis (RA) and psoriatic arthritis …

The biological DMARD (bDMARD) abatacept (Orencia®), a recombinant fusion protein,
selectively modulates a co-stimulatory signal necessary for T-cell activation. In the EU …